Physician profile
Jacob Lewis Ackerman
NPI 1710083050
$2,912.93
in general payments reported to CMS, 2019-2025
15 companies · $327 in 2025
The $327 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2021: $227 · 2022: $34.04 · 2023: $1,689 · 2024: $298 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,168 · Travel and Lodging: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.22 |
| Travel and Lodging | $1,145.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,358.93 | 2019-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $385.68 | 2021-2024 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Aerie Pharmaceuticals, INC. | $365.01 | 2019-2021 | |
| Alcon Vision LLC | $210.51 | 2019-2025 | Clareon, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $155.88 | 2023-2025 | Xiidra, Vyzulta, Miebo |
| Abbvie INC. | $153.55 | 2023-2025 | Durysta, Lumigan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $67.95 | 2019-2021 | |
| Glaukos Corporation | $41.13 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Allergan, INC. | $35.94 | 2021 | |
| Ocular Therapeutix, INC. | $34.98 | 2023-2024 | Dextenza |
| Dompe US, INC. | $32.46 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $19.74 | 2022 | |
| Mallinckrodt Hospital Products INC. | $18.46 | 2025 | Acthar |
| New World Medical,INC. | $18.41 | 2023 | |
| Oyster Point Pharma, INC. | $14.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.